Table 1.
Differentially affected pathways by Ingenuity Pathway Analysis
| Ingenuity canonical pathways | p-value | Ratio | Molecules |
|---|---|---|---|
| Granulocyte adhesion and diapedesis | 4.94E-06 | 7.18E-02 | VCAM1,SDC1,MMP3,MMP10,CLDN7,CCL5,CXCL5,IL18RAP,CXCL10,ITGB2,MMP9,CLDN3,MMP19 |
| Inhibition of matrix metalloproteases | 3.54E-05 | 1.50E-01 | SDC1,MMP3,RECK,MMP10,MMP9,MMP19 |
| MMP19 hepatic fibrosis/hepatic stellate cell activation | 8.91E-05 | 6.45E-02 | 02VCAM1,CTGF,FGFR1,PDGFRA,LBP,CCL5,PDGFC,MMP9,PGF,IL18RAP |
| Regulation of the epithelial-mesenchymal transition pathway | 1.81E-04 | 5.61E-02 | MAP2K6,CDH1,JAG2,WNT10B,ESRP2,FGFR1,PARD6G,JAG1,NOTCH1,MMP9,CLDN3 |
| Agranulocyte adhesion and diapedesis | 2.09E-04 | 5.76E-02 | CXCL10,ITGB2,VCAM1,MMP3,MMP10,CLDN7,CCL5,CXCL5,MMP9,CLDN3,MMP19 |
| HIF1alpha signaling | 2.68E-04 | 7.14E-02 | MMP3,MMP10,PDGFC,LDHA,MMP9,LDHB,PGF,MMP19 |
| Antigen presentation pathway | 3.05E-04 | 1.19E-01 | B2M,PSMB9,HLA-B,PSMB8,TAP1 |
| Bladder cancer signaling | 5.99E-04 | 7.22E-02 | CDH1,MMP3,MMP10,PDGFC,MMP9,PGF,MMP19 |
| IL-8 signaling | 9.59E-04 | 4.44E-02 | ITGB2,GNB4,CDH1,ANGPT2,VCAM1,CCND2,MYL12B,PDGFC,MMP9,PGF |
| Leukocyte extravasation signaling | 1.48E-03 | 4.76E-02 | ITGB2,VCAM1,EDIL3,MMP3,CD44,MMP10,CLDN7,MMP9,CLDN3,MMP19 |
| VDR/RXR activation | 1.63E-03 | 6.82E-02 | CXCL10,SPP1,GADD45A,SEMA3B,VDR,CCL5 |
| Pyruvate fermentation to lactate | 2.53E-03 | 2.22E-01 | LDHA,LDHB |
| ILK signaling | 3.47E-03 | 4.39E-02 | MAP2K6,ITGB2,PARVB,CDH1,VIM,PDGFC,MMP9,DSP,PGF |
| Pathogenesis of multiple sclerosis | 8.71E-03 | 2.00E-01 | CXCL10,CCL5 |
| Sphingosine-1-phosphate signaling | 8.97E-03 | 4.88E-02 | PLCD1,CASP12,CASP1,PDGFRA,CASP4,PDGFC |
| Axonal guidance signaling | 1.04E-02 | 2.90E-02 | WNT10B,BDNF,MMP10,ADAMTS9,PDGFC,SEMA4C,PGF,PLCD1,GNB4,MYL12B,BMP7,SEMA3B,MMP9,SEMA7A |
| Atherosclerosis signaling | 1.39E-02 | 4.35E-02 | ITGB2,VCAM1,MMP3,S100A8,PDGFC,MMP9 |
| Sorbitol degradation I | 1.62E-02 | 2.00E-01 | SORD |
| Asparagine biosynthesis I | 1.62E-02 | 1.25E-01 | ASNS |
| Alanine biosynthesis III | 1.62E-02 | 3.33E-01 | NFS1 |
| Colorectal cancer metastasis signaling | 1.73E-02 | 3.36E-02 | GNB4,CDH1,WNT10B,MMP3,MMP10,PDGFC,MMP9,PGF,MMP19 |
| p53 signaling | 1.75E-02 | 4.63E-02 | TP53INP1,CCND2,GADD45A,PLAGL1,SFN |
| Role of IL-17A in psoriasis | 1.81E-02 | 1.43E-01 | S100A8,CXCL5 |
| Chondroitin sulfate degradation (metazoa) | 2.09E-02 | 8.70E-02 | CD44,HEXA |
| Human embryonic stem cell pluripotency | 2.19E-02 | 3.73E-02 | WNT10B,BDNF,FGFR1,PDGFRA,BMP7,PDGFC |
| Notch signaling | 2.33E-02 | 6.98E-02 | JAG2,JAG1,NOTCH1 |
| Dermatan sulfate degradation (metazoa) | 2.38E-02 | 8.70E-02 | CD44,HEXA |
| Thyroid cancer signaling | 2.66E-02 | 6.82E-02 | CXCL10,CDH1,BDNF |
| Alanine degradation III | 3.21E-02 | 1.67E-01 | GPT2 |
| Alanine biosynthesis II | 3.21E-02 | 1.67E-01 | GPT2 |
| Formaldehyde oxidation II (glutathione-dependent) | 3.21E-02 | 1.00E-01 | ESD |
| Glutamine degradation I | 3.21E-02 | 2.00E-01 | GLS2 |
| GADD45 signaling | 4.09E-02 | 8.33E-02 | CCND2,GADD45A |